keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy resistance ovarian carcinoma

keyword
https://www.readbyqxmd.com/read/29663364/impact-of-iaspp-on-chemoresistance-through-plk1-and-autophagy-in-ovarian-clear-cell-carcinoma
#1
Ka-Kui Chan, Oscar Gee-Wan Wong, Esther Shuk-Ying Wong, Karen Kar-Loen Chan, Philip Pun-Ching Ip, Ka-Yu Tse, Annie Nga-Yin Cheung
Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival...
April 16, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29645088/impact-of-iaspp-on-chemoresistance-through-plk1-and-autophagy-in-ovarian-clear-cell-carcinoma
#2
Ka-Kui Chan, Oscar Gee-Wan Wong, Esther Shuk-Ying Wong, Karen Kar-Loen Chan, Philip Pun-Ching Ip, Ka-Yu Tse, Annie Nga-Yin Cheung
Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival...
April 12, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29587661/characteristics-and-outcome-of-the-coeur-canadian-validation-cohort-for-ovarian-cancer-biomarkers
#3
Cécile Le Page, Kurosh Rahimi, Martin Köbel, Patricia N Tonin, Liliane Meunier, Lise Portelance, Monique Bernard, Brad H Nelson, Marcus Q Bernardini, John M S Bartlett, Dimcho Bachvarov, Walter H Gotlieb, Blake Gilks, Jessica N McAlpine, Mark W Nachtigal, Alain Piché, Peter H Watson, Barbara Vanderhyden, David G Huntsman, Diane M Provencher, Anne-Marie Mes-Masson
BACKGROUND: Ovarian carcinoma is the most lethal gynecological malignancy due to early dissemination and acquired resistance to platinum-based chemotherapy. Reliable markers that are independent and complementary to clinical parameters are needed to improve the management of patients with this disease. The Canadian Ovarian Experimental Unified Resource (COEUR) provides researchers with biological material and associated clinical data to conduct biomarker validation studies. Using standards defined by the Canadian Tissue Repository Network (CTRNet), we have previously demonstrated the quality of the biological material from this resource...
March 27, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29581906/the-cytoreductive-effect-of-radiotherapy-for-small-cell-ovarian-carcinoma-of-the-pulmonary-type-a-case-report-and-review-of-the-literature
#4
Shuhei Terada, Takashi Suzuki, Akihiro Hasegawa, Satoru Nakayama, Hiroshi Adachi
Small cell ovarian carcinoma of the pulmonary type is a rare and highly aggressive tumor for which a suitable treatment strategy has not been established. A 45-year-old woman presented with abdominal swelling, and primary ovarian carcinoma was suspected. The postoperative pathological diagnosis was small cell ovarian carcinoma of the pulmonary type. She also had complicated grade 1 endometrioid carcinoma of the uterine corpus. Three courses of cisplatin and etoposide therapy were administered as adjuvant chemotherapy...
2018: Case Reports in Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29580231/gdf15-predict-platinum-response-during-first-line-chemotherapy-and-can-act-as-a-complementary-diagnostic-serum-biomarker-with-ca125-in-epithelial-ovarian-cancer
#5
Dan Zhao, Xiaobing Wang, Wei Zhang
BACKGROUND: Growth differentiation factor 15 (GDF15) has attracted much interest as a novel biomarker for epithelial ovarian carcinoma (EOC). Research focus has been directed at GDF15 as a diagnostic detection, while the prognostic determination of GDF15 in EOC patients remains to be clearly elucidated. The present study aimed to investigate GDF15 level relative to clinicopathological characters, chemoresponse, and clinical outcome of EOC patients. METHODS: Serum from 122 patients with primary diagnosed EOC were analyzed for GDF15 and serum cancer antigen 125 (CA125)...
March 27, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29572031/helicase-polq-like-helq-as-a-novel-indicator-of-platinum-based-chemoresistance-for-epithelial-ovarian-cancer
#6
Jing Long, Jun-You Zhu, Yong-Bin Liu, Kun Fu, Yan Tian, Pei-Yao Li, Wen-Qing Yang, Si-Yu Yang, Ji-Ye Yin, Gang Yin, Yu Zhang
OBJECTIVE: To investigate the role of HELQ in chemo-resistance of epithelial ovarian carcinoma (EOC), which is a critical factor of patients' prognosis. METHODS: Immunohistochemistry, survival analysis of our 87 EOC patients and bioinformatics analysis of The Cancer Genome Atlas (TCGA) datasets (Nature, 2011) disclosed the clinical importance of HELQ expression. Quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western Blot analyses of EOC tissue were used to confirm it...
March 20, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29567488/blockade-of-nuclear-factor-%C3%AE%C2%BAb-nf-%C3%AE%C2%BAb-pathway-inhibits-growth-and-induces-apoptosis-in-chemoresistant-ovarian-carcinoma-cells
#7
Majid Momeny, Hassan Yousefi, Haniyeh Eyvani, Farima Moghaddaskho, Ali Salehi, Fatemeh Esmaeili, Zivar Alishahi, Farinaz Barghi, Somaye Vaezijoze, Sahar Shamsaiegahkani, Ghazaleh Zarrinrad, Ghazaleh Sankanian, Zahra Sabourinejad, Sepideh Hamzehlou, Davood Bashash, Elaheh S Aboutorabi, Parisa Ghaffari, Ahmad R Dehpour, Seyyed M Tavangar, Javad Tavakkoly-Bazzaz, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Seyed H Ghaffari
Epithelial ovarian cancer (EOC) has exhibited marginal improvement in survival rate, despite advances in surgical debulking and chemotherapy regimens. Although the majority of EOC patients achieve a clinical remission after induction therapy, over 80% relapse and succumb to chemoresistant disease. In this regard, it is of paramount importance to elucidate molecular mechanisms and signaling pathways which promote therapy resistance in EOC in order to devise novel and more effective treatment strategies. In this study, we showed that activation of nuclear factor-κB (NF-κB) is significantly higher in therapy-resistant EOC cells compared to chemosensitive counterparts, which was positively associated with resistance to cisplatin, carboplatin, paclitaxel and erlotinib...
March 19, 2018: International Journal of Biochemistry & Cell Biology
https://www.readbyqxmd.com/read/29565447/cafs-enhance-paclitaxel-resistance-by-inducing-emt-through-the-il%C3%A2-6-jak2-stat3-pathway
#8
Linlin Wang, Fang Zhang, Jian-Ying Cui, Liang Chen, Yue-Ting Chen, Bo-Wen Liu
Carcinoma‑associated fibroblasts (CAFs) are the major components of mesenchymal cells in the inflammatory tumor microenvironment. They are involved in epithelial‑mesenchymal transition (EMT) and chemotherapy resistance by directly contacting with cancer cells or secretory cytokines. In the present study, we examined the role of CAFs in the induction of EMT in ovarian cancer. Primary ovarian cancer cells, CAFs and normal fibroblasts (NFs) were isolated from fresh cancer tissue and cultured for immunohistochemistry studies...
May 2018: Oncology Reports
https://www.readbyqxmd.com/read/29531130/transducin-like-enhancer-of-split-3-tle3-expression-is-associated-with-taxane-sensitivity-in-non-serous-ovarian-carcinoma-in-a-three-cohort-study
#9
Brian Z Ring, Rajmohan Murali, Robert A Soslow, David D L Bowtell, Sian Fereday, Anna DeFazio, Nadia Traficante, Catherine J Kennedy, Alison Brand, Raghwa Sharma, Paul Harnett, Goli Samimi
BACKGROUND: Chemo-resistance is a major challenge in ovarian cancer treatment, resulting in poor survival rates. Identifying markers of treatment response is imperative for improving outcome while minimizing unnecessary side effects. We have previously demonstrated that expression of transducin-like enhancer of split 3 (TLE3) is associated with favorable progression-free survival in taxane-treated ovarian cancer patients with non-serous histology. The purpose of this study was to perform an independent evaluation of the association of TLE3 expression with response to taxane-based chemotherapy in non-serous ovarian cancer, to validate its role as a potential therapeutic response marker for taxane-based chemotherapy...
March 12, 2018: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29453736/reproductive-epidemiology-of-glial-tumors-may-reveal-novel-treatments-high-dose-progestins-or-progesterone-antagonists-as-endocrino-immune-modifiers-against-glioma
#10
REVIEW
Meric A Altinoz, Aysel Ozpinar, Ilhan Elmaci
Female gender, contraceptives, and menopausal hormone replacement treatments containing progesterone analogues associate with higher risk of meningiomas yet with lower risk of gliomas. Progesterone receptor (PR) expression and mifepristone treatment was highly discussed for meningiomas. However, much less is known in regard to progesterone actions in gliomas despite PR expression strongly correlates with their grade. Meningiomas and gliomas may grow faster during gestation; but paradoxically, parousity reduces lifetime risk of gliomas which can be explained with dichotomous cell growth-stimulating and inhibitory actions of progesterone at low versus high levels...
February 17, 2018: Neurosurgical Review
https://www.readbyqxmd.com/read/29435166/acquired-resistance-to-tyrosine-kinase-inhibitors-may-be-linked-with-the-decreased-sensitivity-to-x-ray-irradiation
#11
Maxim Sorokin, Roman Kholodenko, Anna Grekhova, Maria Suntsova, Margarita Pustovalova, Natalia Vorobyeva, Irina Kholodenko, Galina Malakhova, Andrew Garazha, Artem Nedoluzhko, Raif Vasilov, Elena Poddubskaya, Olga Kovalchuk, Leila Adamyan, Vladimir Prassolov, Daria Allina, Denis Kuzmin, Kirill Ignatev, Andreyan Osipov, Anton Buzdin
Acquired resistance to chemotherapy and radiation therapy is one of the major obstacles decreasing efficiency of treatment of the oncologic diseases. In this study, on the two cell lines (ovarian carcinoma SKOV-3 and neuroblastoma NGP-127), we modeled acquired resistance to five target anticancer drugs. The cells were grown on gradually increasing concentrations of the clinically relevant tyrosine kinase inhibitors (TKIs) Sorafenib, Pazopanib and Sunitinib, and rapalogs Everolimus and Temsirolimus, for 20 weeks...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29435041/tbx2-expression-is-associated-with-platinum-sensitivity-of-ovarian-serous-carcinoma
#12
Reiko Tasaka, Takeshi Fukuda, Masahiro Shimomura, Yuta Inoue, Takuma Wada, Masaru Kawanishi, Tomoyo Yasui, Toshiyuki Sumi
The standard treatment for ovarian serous carcinoma comprises maximum debulking surgery and platinum-based chemotherapy. Despite the high response rate to chemotherapy, the majority of patients will be resistant to first-line agents and the prognosis for these patients is particularly poor. At present there are no reliable methods to determine or predict platinum resistance. T-box 2 (TBX2) is widely expressed in cancer cells and is involved in embryonic development and cell cycle regulation. TBX2 enables cells to bypass senescence through its ability to repress the cell cycle regulators p21 and p14ARF; silencing TBX2 induces senescence...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29413758/therapeutic-effect-of-%C3%AE-emitting-224ra-labeled-calcium-carbonate-microparticles-in-mice-with-intraperitoneal-ovarian-cancer
#13
Sara Westrøm, Tina B Bønsdorff, Øyvind S Bruland, Roy H Larsen
BACKGROUND: Ovarian cancer patients with chemotherapy-resistant residual microscopic disease in the peritoneal cavity have a considerable need for new treatment options. Alpha-emitting radionuclides injected intraperitoneally may be an attractive therapeutic option in this situation as they are highly cytotoxic, while their short range in tissues can spare surrounding radiosensitive organs in the abdomen. Herein we evaluate the therapeutic efficacy of a novel α-emitting compound specifically designed for intracavitary radiation therapy...
January 27, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29351920/exceptional-response-to-pembrolizumab-in-a-metastatic-chemotherapy-radiation-resistant-ovarian-cancer-patient-harboring-a-cd274-pd-l1-genetic-rearrangement
#14
Stefania Bellone, Natalia Buza, Jungmin Choi, Luca Zammataro, Laurie Gay, Julia A Elvin, David L Rimm, Yuting Liu, Elena Ratner, Peter E Schwartz, Alessandro D Santin
PURPOSE: Ovarian carcinoma no longer responsive to surgery and chemotherapy remains an incurable disease. Alternative therapeutic options remain desperately needed. EXPERIMENTAL DESIGN: We describe a heavily pretreated ovarian cancer patient with recurrent disease experiencing a remarkable clinical response to treatment with the anti-PD1 immune check-point inhibitor pembrolizumab. The clinical, pathological, and genomic characteristics of this exceptional ovarian cancer responder were carefully investigated using immunohistochemistry (IHC), quantitative multiplex fluorescence methods (ie, automated quantitative analysis, AQUA) and whole exome sequencing (WES) techniques...
January 19, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29344971/clear-cell-carcinomas-of-the-ovary-and-kidney-clarity-through-genomics
#15
REVIEW
Jennifer X Ji, Yi Kan Wang, Dawn R Cochrane, David G Huntsman
Clear cell ovarian carcinoma (CCOC) and clear cell renal cell carcinoma (ccRCC) both feature clear cytoplasm due to the accumulation of cytoplasmic glycogen. Genomic studies have demonstrated several mutational similarities between these two diseases including frequent alterations in the chromatin remodeling SWI/SNF and cellular proliferation PI3K/mTOR pathways, as well as a shared hypoxia-like mRNA expression signature. Although many targeted treatment options have been approved for advance stage ccRCC, CCOC patients are still treated with conventional platinum and taxane chemotherapy, to which they are resistant...
January 17, 2018: Journal of Pathology
https://www.readbyqxmd.com/read/29340100/the-inhibition-of-cordycepin-on-cancer-stemness-in-tgf-beta-induced-chemo-resistant-ovarian-cancer-cell
#16
Chia-Woei Wang, Bao-Hong Lee, Chen-Jei Tai
Chemotherapy is one of the main approach for ovarian cancer. Cancer stem cells (CSCs) escape chemotherapy and lead to chemoresistance. We previously demonstrated that cordycepin (Cd) inhibited metastasis in human ovarian carcinoma cells, the aim of this study is to investigate the effects of Cd on ovarian cancer stemness. TGF-beta was used to induce chemoresistance of chemotherapeutic agent cisplatin in SKOV-3 ovarian cancer cells. After treating with 100 μM of Cd, cell viability, the percentage of cancer stem cells, and the levels of matrix metalloproteinases (MMPs) were decreased in TGF-beta-induced SKOV-3 cells...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29339543/genes-predisposed-to-dna-hypermethylation-during-acquired-resistance-to-chemotherapy-are-identified-in-ovarian-tumors-by-bivalent-chromatin-domains-at-initial-diagnosis
#17
Edward Curry, Constanze Zeller, Nahal Masrour, Darren K Patten, John Gallon, Charlotte S Wilhelm-Benartzi, Sadaf Ghaem-Maghami, David D Bowtell, Robert Brown
Bivalent chromatin domains containing both active H3K4me3 and repressive H3K27me3 histone marks define gene sets poised for expression or silencing in differentiating embryonic stem (ES) cells. In cancer cells, aberrantly poised genes may facilitate changes in transcriptional states after exposure to anticancer drugs. In this study, we used ChIP-seq to characterize genome-wide positioning of H3K4me3- and H3K27me3-associated chromatin in primary high-grade serous ovarian carcinomas and in normal ovarian surface and fallopian tube tissue...
March 15, 2018: Cancer Research
https://www.readbyqxmd.com/read/29296226/annexin-a4-fucosylation-enhances-its-interaction-with-the-nf-kb-p50-and-promotes-tumor-progression-of-ovarian-clear-cell-carcinoma
#18
Huimin Wang, Lu Deng, Mingbo Cai, Huiyu Zhuang, Liancheng Zhu, Yingying Hao, Jian Gao, Juanjuan Liu, Xiao Li, Bei Lin
Objective: To study the structural relationship between annexin A4 and the Lewis y antigen and compare their expression and significance in ovarian clear cell carcinoma, and to explore how annexin A4 fucose glycosylation effects the interaction between annexin A4 and NF-kB p50, and how it promotes tumour progression of ovarian clear cell carcinoma. Methods: Structural relationships between annexin A4 and Lewis y antigen were detected using immunoprecipitation. Annexin A4 and Lewis y antigen expression in various subtypes of ovarian cancer tissues was detected by immunohistochemistry, and the relation between their expression was examined...
December 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/29296209/the-prognostic-value-of-ki67-in-ovarian-high-grade-serous-carcinoma-an-11-year-cohort-study-of-chinese-patients
#19
Ming Chen, Shuzhong Yao, Qinghua Cao, Meng Xia, Junxiu Liu, Mian He
Objective: This study sought to assess the prognostic role of Ki67 in primary ovarian high-grade serous carcinoma (HGSC) and to determine whether Ki67 expression can predict responsiveness to platinum and paclitaxel chemotherapy. Results: A total of 318 women were included in the analysis and the median follow-up time was 48 months (range, 3-150 months). Ki67 proliferation indices ranged from 3% to 95% with a median of 40%. Using 40% as the cut-off value for the Ki67 index, we classified 141 patients as having low Ki67 expression and 177 patients as having high Ki67 expression...
December 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/29192345/transporter-mediated-interaction-between-platinum-drugs-and-sorafenib-at-the-cellular-level
#20
Verena Schneider, Selim Chaib, Claudia Spanier, Mandy Knapp, Violeta Moscvin, Laura Scordovillo, Alessandra Ewertz, Ulrich Jaehde, Ganna V Kalayda
Combining the multikinase inhibitor sorafenib with the platinum-based chemotherapy of solid tumors was expected to improve treatment outcome. However, in many clinical trials, no benefit from sorafenib addition to the platinum-containing regimen could be demonstrated. Moreover, in some studies, decreased survival of ovarian cancer patients as well as non-small cell lung cancer patients with squamous cell histology was observed. The aim of this study was to investigate the cellular mechanisms of the pharmacological interaction between platinum drugs and sorafenib in different cancer cell lines...
November 30, 2017: AAPS Journal
keyword
keyword
100097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"